BIOMAT Database Logo BIOMAT Database Logo

Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. 2016

W Huang, and Z Dong, and Y Chen, and F Wang, and C J Wang, and H Peng, and Y He, and G Hangoc, and K Pollok, and G Sandusky, and X-Y Fu, and H E Broxmeyer, and Z-Y Zhang, and J-Y Liu, and J-T Zhang
Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA.

Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in malignant tumors and has important roles in multiple aspects of cancer aggressiveness. Thus targeting STAT3 promises to be an attractive strategy for treatment of advanced metastatic tumors. Although many STAT3 inhibitors targeting the SH2 domain have been reported, few have moved into clinical trials. Targeting the DNA-binding domain (DBD) of STAT3, however, has been avoided due to its 'undruggable' nature and potentially limited selectivity. In a previous study, we reported an improved in silico approach targeting the DBD of STAT3 that resulted in a small-molecule STAT3 inhibitor (inS3-54). Further studies, however, showed that inS3-54 has off-target effect although it is selective to STAT3 over STAT1. In this study, we describe an extensive structure and activity-guided hit optimization and mechanistic characterization effort, which led to identification of an improved lead compound (inS3-54A18) with increased specificity and pharmacological properties. InS3-54A18 not only binds directly to the DBD and inhibits the DNA-binding activity of STAT3 both in vitro and in situ but also effectively inhibits the constitutive and interleukin-6-stimulated expression of STAT3 downstream target genes. InS3-54A18 is completely soluble in an oral formulation and effectively inhibits lung xenograft tumor growth and metastasis with little adverse effect on animals. Thus inS3-54A18 may serve as a potential candidate for further development as anticancer therapeutics targeting the DBD of human STAT3 and DBD of transcription factors may not be 'undruggable' as previously thought.

UI MeSH Term Description Entries
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic

Related Publications

W Huang, and Z Dong, and Y Chen, and F Wang, and C J Wang, and H Peng, and Y He, and G Hangoc, and K Pollok, and G Sandusky, and X-Y Fu, and H E Broxmeyer, and Z-Y Zhang, and J-Y Liu, and J-T Zhang
Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.
September 2018, European journal of medicinal chemistry,
W Huang, and Z Dong, and Y Chen, and F Wang, and C J Wang, and H Peng, and Y He, and G Hangoc, and K Pollok, and G Sandusky, and X-Y Fu, and H E Broxmeyer, and Z-Y Zhang, and J-Y Liu, and J-T Zhang
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.
November 2019, Cancer cell,
W Huang, and Z Dong, and Y Chen, and F Wang, and C J Wang, and H Peng, and Y He, and G Hangoc, and K Pollok, and G Sandusky, and X-Y Fu, and H E Broxmeyer, and Z-Y Zhang, and J-Y Liu, and J-T Zhang
Targeting GLI1 and GLI2 with small molecule inhibitors to suppress GLI-dependent transcription and tumor growth.
September 2023, Pharmacological research,
W Huang, and Z Dong, and Y Chen, and F Wang, and C J Wang, and H Peng, and Y He, and G Hangoc, and K Pollok, and G Sandusky, and X-Y Fu, and H E Broxmeyer, and Z-Y Zhang, and J-Y Liu, and J-T Zhang
Small molecule targeting FOXM1 DNA binding domain exhibits anti-tumor activity in ovarian cancer.
June 2022, Cell death discovery,
W Huang, and Z Dong, and Y Chen, and F Wang, and C J Wang, and H Peng, and Y He, and G Hangoc, and K Pollok, and G Sandusky, and X-Y Fu, and H E Broxmeyer, and Z-Y Zhang, and J-Y Liu, and J-T Zhang
Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.
August 2014, Journal of medicinal chemistry,
W Huang, and Z Dong, and Y Chen, and F Wang, and C J Wang, and H Peng, and Y He, and G Hangoc, and K Pollok, and G Sandusky, and X-Y Fu, and H E Broxmeyer, and Z-Y Zhang, and J-Y Liu, and J-T Zhang
Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis.
April 2008, Immunological reviews,
W Huang, and Z Dong, and Y Chen, and F Wang, and C J Wang, and H Peng, and Y He, and G Hangoc, and K Pollok, and G Sandusky, and X-Y Fu, and H E Broxmeyer, and Z-Y Zhang, and J-Y Liu, and J-T Zhang
Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain.
January 2022, Frontiers in pharmacology,
W Huang, and Z Dong, and Y Chen, and F Wang, and C J Wang, and H Peng, and Y He, and G Hangoc, and K Pollok, and G Sandusky, and X-Y Fu, and H E Broxmeyer, and Z-Y Zhang, and J-Y Liu, and J-T Zhang
Correction to Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor.
February 2017, Journal of medicinal chemistry,
W Huang, and Z Dong, and Y Chen, and F Wang, and C J Wang, and H Peng, and Y He, and G Hangoc, and K Pollok, and G Sandusky, and X-Y Fu, and H E Broxmeyer, and Z-Y Zhang, and J-Y Liu, and J-T Zhang
Discovery of novel STAT3 DNA binding domain inhibitors.
August 2021, Future medicinal chemistry,
W Huang, and Z Dong, and Y Chen, and F Wang, and C J Wang, and H Peng, and Y He, and G Hangoc, and K Pollok, and G Sandusky, and X-Y Fu, and H E Broxmeyer, and Z-Y Zhang, and J-Y Liu, and J-T Zhang
Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma.
March 2021, Journal of experimental & clinical cancer research : CR,
Copied contents to your clipboard!